Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER versus TAZIDIME IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER versus TAZIDIME IN PLASTIC CONTAINER.
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER vs TAZIDIME IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP-3, leading to cell lysis and death. It is a beta-lactam antibiotic with activity against Gram-negative bacteria including Pseudomonas aeruginosa.
1-2 g IV every 6-8 hours; maximum 12 g/day.
1-2 g intravenously every 8 hours for most infections; up to 2 g every 6 hours for severe infections, particularly in neutropenic patients or those with cystic fibrosis.
None Documented
None Documented
0.8-1.4 hours (normal renal function); ~2-6 hours in renal impairment; prolonged in neonates and elderly
Terminal elimination half-life 1.7-2.0 hours in adults with normal renal function; prolonged to 12-30 hours in end-stage renal disease.
Renal: 50-60% unchanged; biliary: 20-30%; fecal: <5%
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for <1%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic